SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics priced a $55.0M registered direct offering of…

Outlook Therapeutics, Inc. · 8-K filed Aug 14, 2026 at 08:36 ET

At the news

BEARISHIMPACT 6/10

8-K filed Aug 14, 2026 at 08:36 ET

Outlook Therapeutics priced a $55.0M registered direct offering of 55,555,556 shares of common stock and accompanying warrants to purchase up to 55,555,556 shares, at a combined price of $0.99 per unit. The underwriters also exercised their option to purchase additional warrants covering 8,333,333 shares. The offering is heavily dilutive (~33% of current market cap in base shares alone) and the warrants, exercisable at $1.10 for 5 years, create additional overhang. The company's largest stockholder, CEO, and CFO participated, signaling some insider confidence, but the dilutive structure and low offering price relative to the $166M market cap are clearly negative for existing holders.

  • 55,555,556 shares + 55,555,556 warrants sold at $0.99/unit ($0.98 per share + $0.01 per warrant)
  • Gross proceeds of approximately $55.0 million before expenses and underwriting discounts
  • Underwriters' option for 8,333,333 additional shares/warrants was exercised for warrants only
  • Warrants have a $1.10 exercise price, 5-year term, exercisable immediately

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access